HK Stock Market Move | METIS TECHBIO-P (07666) surged over 33% as Moderna's significant breakthrough opens up new possibilities for mRNA. The company possesses the capability to develop mRNA tumor vaccines.

METIS TECHBIO-P (07666) surged over 33%, and as of the time of writing, it had risen 31.74% to reach HKD 15.44, with a trading volume of HKD 87.6427 million. In news, on August 19, Moderna and Merck announced that their jointly developed melanoma mRNA cancer vaccine had reached its primary endpoint in a Phase III clinical trial, becoming the world's first clinically validated mRNA therapeutic cancer vaccine, confirming the feasibility and commercial value of mRNA technology for cancer treatment. This news led to Moderna's stock price skyrocketing by 176.97%, and the market anticipates that the valuation system for domestic mRNA technology will be reshaped. It is reported that Ditaike Technology's AI-powered end-to-end mRNA design + LNP delivery + protein design NanoForge platform possesses both mRNA tumor vaccine development capabilities and LNP delivery capabilities. MTS-107 is an important pipeline for the company in tumor treatment, exploring the treatment of HPV-related cancers by targeting the spleen for LNP delivery of mRNA, combined with E6/E7 dual antigens and immune activation mechanisms. MTS-105, on the other hand, utilizes liver-targeted LNP to allow liver cells to produce and secrete TCE in situ, which then acts in tumor tissues.